South San Francisco, CA, United States of America

Deepak Sampath

USPTO Granted Patents = 17 (Patent Applications = 15)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 16)

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 123(Granted Patents)

Location History:

San Francisco, CA (US) (2012 - 2018)
South San Francisco, CA (US) (2013 - 2023)

Company Filing History:

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

patents

where one patent can have more than one assignee

Years Active: 2012-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11590128 - Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor (2023-02-28),

2. 11413282 - Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor (2022-08-16),

3. 11110087 - Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor (2021-09-07),

4. 10993942 - Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor (2021-05-04),

5. 10959993 - Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer (2021-03-30),

6. 10898570 - Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor (2021-01-26),

7. 10092567 - Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use (2018-10-09),

8. 9855270 - Methods and compositions for modulating estrogen receptor mutants (2018-01-02),

9. 9717730 - Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use (2017-08-01),

10. 9682082 - Combinations of AKT and MEK inhibitor compounds, and methods of use (2017-06-20),

11. 9610289 - Combinations of AKT inhibitor compounds and erlotinib, and methods of use (2017-04-04),

12. 9539251 - Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor (2017-01-10),

13. 9346789 - Combinations of AKT inhibitor compounds and abiraterone, and methods of use (2016-05-24),

14. 9150549 - Combinations of AKT inhibitor compounds and erlotinib, and methods of use (2015-10-06),

15. 9107926 - Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer (2015-08-18),

Title: Deepak Sampath: Innovator in Cancer Therapy

Introduction

Deepak Sampath is a prominent inventor based in South San Francisco, CA. He has made significant contributions to the field of cancer treatment, holding a total of 17 patents. His work focuses on innovative therapies that target specific cancer types, particularly those expressing CD20.

Latest Patents

One of his latest patents involves a combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor. This invention is directed towards treating patients suffering from cancer, specifically targeting CD20-expressing cancers. The combination therapy aims to enhance the effectiveness of treatment by utilizing both the anti-CD20 antibody and the BCL-2 inhibitor.

Career Highlights

Deepak has worked with notable companies in the pharmaceutical industry, including Genentech, Inc. and Hoffmann-La Roche Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to cancer therapy.

Collaborations

Throughout his career, Deepak has collaborated with talented professionals, including Michelle Nannini and Jeffrey Wallin. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Deepak Sampath is a key figure in the field of cancer therapy, with a focus on innovative combination treatments. His contributions through his patents and collaborations continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.